Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of gypensapogenin B in anti-tubercle bacillus drugs
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of anti-tuberculosis and drugs, applied in the application field of preparing anti-tuberculosis drugs, to achieve the effect of highlighting substantive features, broad application prospects, and expanding types
Active Publication Date: 2014-04-16
顾咏亮
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, due to the irregular treatment and management of tuberculosis patients, irregular chemotherapy and abuse of anti-tuberculosis drugs, the drug resistance of tuberculosis is becoming more and more serious, and the change of drug resistance tends to be multi-drug resistance at the same time. great difficulty at work
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0016] Example 1: Preparation of Gypensapogenin B tablets of the compound involved in the present invention:
[0017] Take 20 grams of compound Gypensapogenin B, add 180 grams of conventional excipients for preparing tablets, mix them, and prepare 1,000 tablets with a conventional tablet press.
Embodiment 2
[0018] Example 2: Preparation of the compound Gypensapogenin B capsule of the present invention:
[0019] Take 20 grams of the compound Gypensapogenin B, add 180 grams of conventional auxiliary materials for preparing capsules, such as 180 grams of starch, and mix them well, and encapsulate them to make 1000 tablets.
[0020] The following pharmacodynamic experiments will further illustrate its drug activity.
experiment example 1
[0021] Experimental Example 1 Determination of the absolute concentration of Gypensapogenin B against BCG (BCG) by solid medium dilution method
[0022] Scrape the BCG culture from the inclined surface, add it to 3ml Middlebrook 7H9 broth medium, add a small amount of glass beads, tighten the cap of the test tube, grind vigorously on a vortex shaker, and compare it to a standard MacFarland turbidity tube (MacFarland No.1). ) Turbidity, that is, 1mg / ml Bacille Calmette-Guerin (BCG) bacterial suspension.
[0023] Dilute Gypensapogenin B with DMSO into a high-concentration stock solution, dilute the stock solution with sterile ultrapure water containing 5% Tween-80 to the required concentration, add the diluted Gypensapogenin B to 4ml Middlebrook 7H11 agar medium according to the required dose (The medium has been autoclaved at 121°C for 15 minutes and cooled to 50~55°C), mix well, and make Gypensapogenin B with concentrations of 6.0 ug / ml, 4.0 ug / ml, 3.0 ug / ml, 2.0 ug / ml, 1.5 ug / ml,...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of gypensapogenin B to preparation of anti-tubercle bacillus drugs. According to the high tubercle bacillus morbidity and the emergence of mycobacterium tuberculosis multiple-resistant strain, the tubercle bacillus morbidity and mortality are one the rise; and gypensapogenin B has remarkable tubercle bacillus suppression activity and good application prospect. The application of gypensapogenin B to the preparation of the anti-tubercle bacillus drugs is firstly publicized, the skeleton type is brand-new, the tubercle bacillus suppression activity is unexpectedly strong and the possibility of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in the prevention and treatment of the tubercle bacillus infection is made at the same time.
Description
Technical field [0001] The invention relates to the application field of pharmaceutical compounds, in particular to the application of Gypensapogenin B in the preparation of anti-tuberculosis drugs. Background technique [0002] In recent years, the incidence of tuberculosis in the world has been increasing. According to estimates by the World Health Organization (WHO), the current global population infected with Mycobacterium tuberculosis (MTB) accounts for one third of the world’s population, of which 5-10% The infected person becomes a tuberculosis patient. There are 1.3 million cases of active tuberculosis in my country every year, among which about 600,000 cases are infectious tuberculosis, among which about 600,000 cases are infectious tuberculosis. It is one of the countries with a high burden of tuberculosis in the world. [0003] Since the advent of anti-tuberculosis drugs, the treatment of tuberculosis has made an epoch-making change. However, because the treatment and ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
